Annals of the Rheumatic Diseases最新文献

{"title":"Minimally invasive retrieval and characterisation of tenosynovial tissue in rheumatoid arthritis: a novel approach to study at-risk, active, and remission stages.","authors":"Lavinia Agra Coletto, Hanna W van Steenbergen, Clara Di Mario, Marco Gessi, Barbara Tolusso, Denise Campobasso, Domenico Somma, Pierluigi Rizzuti, Dario Bruno, Pietro Rubortone, Beatrice Fresch, Tommaso Hubert, Natacha Goulas, Luca Petricca, Maria Rita Gigante, Viviana A Pacucci, Simone Perniola, Aziza Elmesmari, Carlo Tur, Roberta Benvenuto, Elisa Gremese, Mariola Kurowska-Stolarska, Marco Maria Lizzio, Maria Antonietta D'Agostino, Annette H M van der Helm-van Mil, Stefano Alivernini","doi":"10.1016/j.ard.2025.02.014","DOIUrl":"10.1016/j.ard.2025.02.014","url":null,"abstract":"<p><strong>Objectives: </strong>Tenosynovial inflammation is a hallmark of rheumatoid arthritis (RA), even in the preclinical phase. However, tenosynovium retrieval and characterisation is beyond the current state-of-the-art. We aimed to (1) assess the rate of magnetic resonance imaging (MRI)-detected tenosynovitis in the wrists of patients with preclinical and clinical RA; (2) develop a technique for tenosynovium retrieval; and (3) characterise its cellular composition across disease phases, including the comparison to adjacent synovium.</p><p><strong>Methods: </strong>In total, 834 MRI wrist scans were analysed to assess extensor/flexor tendon tenosynovitis rate (168 autoantibody-positive clinical suspect arthralgia (CSA), 473 naïve to treatment RA, and 193 healthy controls). An ultrasound-guided minimally invasive technique was developed to collect tenosynovium from the wrist extensor tendons in an independent cohort: 16 autoantibody-positive CSA patients, 41 RA patients (14 of whom with adjacent synovium with comparable ultrasound-detected inflammation), and 8 osteoarthritis (OA) patients. Tissue representativity, lining hyperplasia, and inflammatory infiltrate degree were assessed by haematoxylin and eosin staining and immunohistochemistry (CD55, CD68, CD3, CD20, CD138, and CD21). Safety and tolerability were assessed.</p><p><strong>Results: </strong>Tenosynovitis of the wrist extensors/flexor tendons was observed in 34% of CSA and 68% of RA patient compared to 8% in healthy. Tenosynovium was successfully retrieved in 89.7% of cases without severe adverse events. Tenosynovial lining hyperplasia and inflammatory infiltrate were significantly higher in active RA than CSA patients without ultrasound-detected subclinical inflammation and RA remission, and comparable to inflamed adjacent synovium. CSA patients with subclinical inflammation showed early CD3^pos and CD55^pos cells enrichment compared to OA controls.</p><p><strong>Conclusions: </strong>Tenosynovium is frequently inflamed and readily accessible in CSA and RA. Future molecular studies of tenosynovial biopsies will advance understanding of the transition from pre-RA to RA.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":"949-959"},"PeriodicalIF":20.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143727661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Greetings from the editor 2025/2.","authors":"Josef Smolen","doi":"10.1016/j.ard.2025.05.012","DOIUrl":"https://doi.org/10.1016/j.ard.2025.05.012","url":null,"abstract":"","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":"84 6","pages":"883-884"},"PeriodicalIF":20.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Mediterranean spring-the second revolution (and the first) in the management of familial Mediterranean fever.","authors":"Gil Amarilyo","doi":"10.1016/j.ard.2025.02.006","DOIUrl":"https://doi.org/10.1016/j.ard.2025.02.006","url":null,"abstract":"","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":"84 6","pages":"885-887"},"PeriodicalIF":20.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update.","authors":"Linda Rüegg, Andrea Pluma, Sabrina Hamroun, Irene Cecchi, Luis Fernando Perez-Garcia, Philip O Anderson, Laura Andreoli, Sara Badreh Wirström, Vladimira Boyadhzieva, Christina Chambers, Nathalie Costedoat-Chalumeau, Radboud J E M Dolhain, Rebecca Fischer-Betz, Ian Giles, Carina Gøtestam-Skorpen, Maria Hoeltzenbein, Francesca Marchiori, Karoline Mayer-Pickel, Anna Molto, Catherine Nelson-Piercy, Ole Haagen Nielsen, Angela Tincani, Marianne Wallenius, Astrid Zbinden, Yvette Meissner, Axel Finckh, Frauke Förger","doi":"10.1016/j.ard.2025.02.023","DOIUrl":"10.1016/j.ard.2025.02.023","url":null,"abstract":"<p><strong>Objectives: </strong>To update the existing European Alliance of Associations for Rheumatology (EULAR) points to consider (PtC) for use of antirheumatic drugs in reproduction, pregnancy, and lactation, including additional drugs and adverse outcomes as well as paternal drug safety.</p><p><strong>Methods: </strong>According to the EULAR standardised operating procedures, an international task force (TF) defined the questions for a systematic literature review, followed by formulation of the updated statements. A predefined voting process was applied to each overarching principle and statement. Level of evidence and strength of recommendation were assigned, and participants finally provided their level of agreement for each item.</p><p><strong>Results: </strong>The TF proposes 5 overarching principles and 12 recommendations for the use of antirheumatic drugs before and during pregnancy, through lactation, and in male patients. The current evidence indicates that synthetic disease-modifying antirheumatic drugs (DMARDs) compatible with pregnancy include antimalarials, azathioprine, colchicine, cyclosporine, sulfasalazine, and tacrolimus. Regarding nonsteroidal anti-inflammatory drugs (NSAIDs) and glucocorticoids, a more restrictive approach to their use during pregnancy is recommended. Based on an individualised risk-benefit assessment, all tumour necrosis factor inhibitor (TNFi) biologic DMARDs (bDMARDs) can be used throughout pregnancy, and non-TNFi bDMARDs may be used if needed. In relation to lactation, compatible drugs include antimalarials, azathioprine, colchicine, cyclosporine, glucocorticoids, intravenous immunoglobulin (IVIG), NSAIDs, sulfasalazine, and tacrolimus. All bDMARDs are considered compatible with breastfeeding. Concerning the use of drugs in men, compatible options include antimalarials, azathioprine, colchicine, cyclosporine, IVIG, leflunomide, methotrexate, mycophenolate, NSAIDs, glucocorticoids, sildenafil, sulfasalazine, tacrolimus, and bDMARDs.</p><p><strong>Conclusions: </strong>The updated recommendations provide consensus guidance and will help to improve the quality of care of patients during the phases of reproduction, pregnancy, and lactation.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":"910-926"},"PeriodicalIF":20.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143952903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Annals of the Rheumatic Diseases collection on axial spondyloarthritis (2022-2024): advances in the field.","authors":"Sofia Ramiro, Désirée van der Heijde","doi":"10.1016/j.ard.2025.03.005","DOIUrl":"10.1016/j.ard.2025.03.005","url":null,"abstract":"<p><p>During the period from 2022 to 2024, Annals of the Rheumatic Diseases published a series of articles dedicated to significant advancements in axial spondyloarthritis (axSpA). These articles spanned across diverse areas including translational science, epidemiology, disease outcomes, imaging, management, and updated clinical recommendations and consensus statements supported by new evidence.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":"888-893"},"PeriodicalIF":20.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143971016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment with methotrexate plus oral prednisolone versus triple therapy (methotrexate/sulfasalazine/hydroxychloroquine) plus intra-articular glucocorticoids in early rheumatoid arthritis: a prespecified nonrandomised subgroup analysis of clinical and radiographic data at 48 weeks from the NORD-STAR trial's conventional treatment arm.","authors":"Merete Lund Hetland, Marte S Heiberg, Tuulikki Sokka-Isler, Anna Rudin, Mikkel Østergaard, Espen Haavardsholm, Jarno Rutanen, Ronald van Vollenhoven, Gerdur Grondal, Lykke Midtbøll Ørnbjerg, Pernille Bøyesen, Jon Lampa, Michael Nurmohamed, Bjorn Gudbjornsson, Till Uhlig, Aulikki Kononoff, Kristina Lend, Simon Krabbe, Inge C Olsen, Joe Sexton, Kim Hørslev-Petersen","doi":"10.1016/j.ard.2025.03.002","DOIUrl":"10.1016/j.ard.2025.03.002","url":null,"abstract":"<p><strong>Objectives: </strong>In the NOrdic Rheumatic Diseases Strategy Trials And Registries (NORD-STAR) trial, the active conventional arm had 2 nonrandomised regimens: arm 1A (oral group; Sweden, Norway, Netherlands, and Iceland) and arm 1B (injection group; Denmark and Finland). We report clinical, patient-reported, safety, and radiographic outcomes after 48 weeks.</p><p><strong>Methods: </strong>Oral group received methotrexate plus oral prednisolone (20.0 mg/d, tapered rapidly, discontinued week 36); Injection group received triple therapy (methotrexate, sulphasalazine, hydroxychloroquine) and mandatory intra-articular glucocorticoid injections. The primary end point was analysed by logistic regression with several approaches for handling missing outcomes.</p><p><strong>Results: </strong>In total, 137 and 80 patients were included in the oral group and injection group; 78% vs. 89% completed, respectively. At 48 weeks, adjusted clinical disease activity index remission ≤2.8 rates (95% CI) were 36% (28-44) and 55% (42-68), respectively; the risk difference (primary outcome) was 19% (2-35). Similarly, key secondary clinical, patient-reported and safety outcomes showed numerically better results in the injection group vs oral group, for example, infections occurred in 53% vs 30%, respectively. Radiographic progression (Δtotal van der Heijde-modified Sharp Score) was low: oral group: adjusted mean, 0.26 (95% CI, 0.08-0.43); injection group: adjustedd mean, 0.80 (95% CI, 0.55-1.05). Cumulative dose of oral/intra-articular glucocorticoids (median) was 1905 mg prednisolone for the oral group and 165 mg for the injection group.</p><p><strong>Conclusions: </strong>In treatment-naïve patients with early rheumatoid arthritis, triple therapy and mandatory glucocorticoid joint injections had numerically better clinical outcomes, fewer withdrawals, fewer adverse events, and lower cumulative dose of glucocorticoids, but slightly worse radiographic outcomes than treatment with methotrexate and oral prednisolone. These findings, although nonrandomised, suggest a potential for optimising treatment strategy with conventional therapies in early rheumatoid arthritis.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":"937-948"},"PeriodicalIF":20.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143787497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and safety of the recombinant zoster vaccine in individuals ≥50 years of age with rheumatoid arthritis: a matched cohort and self-controlled case series study.","authors":"Emily Rayens, Lina S Sy, Lei Qian, Jun Wu, Bradley K Ackerson, Yi Luo, Yanjun Cheng, Antony T Lin, Zendi Solano, Justine De Jesus, Britta Amundsen, Ana Florea, Jennifer H Ku, Elizabeth Chmielewski-Yee, Driss Oraichi, Harry Seifert, Huifeng Yun, Hung Fu Tseng","doi":"10.1016/j.ard.2025.01.045","DOIUrl":"10.1016/j.ard.2025.01.045","url":null,"abstract":"<p><strong>Objectives: </strong>In an interim analysis, we evaluated vaccine effectiveness (VE) against herpes zoster (HZ) and postherpetic neuralgia (PHN) and safety of recombinant zoster vaccine (RZV) in adults aged ≥50 years with rheumatoid arthritis (RA).</p><p><strong>Methods: </strong>VE was assessed using a retrospective matched cohort analysis of Kaiser Permanente Southern California members aged ≥50 years with RA receiving 2 RZV doses (≥4 weeks apart) and matched up to 1:3 to RZV-unvaccinated individuals. Stratified Cox proportional hazards regression was used to estimate adjusted hazard ratios and VE against HZ and PHN. Safety was assessed using a self-controlled case series analysis of chart-confirmed RA flare within 30 days after any RZV vaccination versus comparison periods. The relative risk (RR) was estimated using conditional Poisson regression.</p><p><strong>Results: </strong>In adults ≥50 years with RA (2-dose vaccinated: 1926; unvaccinated: 5746), the adjusted VE of 2 RZV doses against HZ was 60.7% (95% CI, 41.0%-73.8%); in a subgroup analysis among those who received 2 doses 4 weeks to 6 months apart, VE against HZ was 57.9% (95% CI, 34.4%-73.0%). Adjusted VE of 2 RZV doses against PHN was 88.7% (95% CI, 12.1%-98.5%). Among 2606 adults with RA who received ≥1 RZV dose, no increased risk of RA flares within 30 days after RZV vaccination was observed (RR, 1.02; 95% CI, 0.75-1.37).</p><p><strong>Conclusions: </strong>Among adults ≥50 years with RA, 2 RZV doses provided protection against HZ and PHN. The study did not observe an increased risk of RA flares within 30 days following RZV vaccination.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":"960-969"},"PeriodicalIF":20.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143466734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic delay and less intensive therapy for people with psoriatic arthritis compared with rheumatoid arthritis: a study nested within an English and Welsh audit data set.","authors":"Rachel A Charlton, Emer Gates, Laura C Coates, James Galloway, Neil McHugh, Anita McGrogan, Simon Hackett, Melanie Brooke, Charlotte Cavill, William Tillett","doi":"10.1016/j.ard.2025.02.020","DOIUrl":"10.1016/j.ard.2025.02.020","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to compare time to diagnosis among patients with psoriatic arthritis (PsA) with that of patients with rheumatoid arthritis (RA) and compare initial treatment and outcomes.</p><p><strong>Methods: </strong>Patients with PsA were identified from the National Early Inflammatory Arthritis Audit between May 2018 and October 31, 2019, and matched to patients with RA (1:1) on age and sex. Patient characteristics and time to diagnosis were compared between PsA and RA groups. Further comparisons were made, restricted to matched pairs of patients with polyarticular PsA, including disease activity, disease impact, and treatment initiation.</p><p><strong>Results: </strong>In total, 2120 patients with PsA were matched to patients with RA, of which 1250 had polyarticular disease. Symptom duration before referral was longer in patients with PsA than that in patients with RA. Patients with PsA had a longer time from general practitioner (GP) presentation to diagnosis (mean, 112 v 89 days; hazard ratio [HR], 0.87; 95% CI, 0.79-0.96; P = .007), including a delay in diagnosis once referrals were received in secondary care (HR, 0.86; 95% CI, 0.80-0.95; P = .002). In patients with polyarticular disease, less disease-modifying antirheumatic drugs (DMARDs) were prescribed at baseline to patients with PsA compared with those to patients with RA (54.0% and 69.0%, respectively; P < .001). Patients with RA had a higher Disease Activity Score in 28 joints at baseline, but by 3 months, the average score was 0.27 (95% CI, 0.13-0.4) higher in patients with PsA.</p><p><strong>Conclusions: </strong>Compared with patients with RA, patients with PsA have a longer duration of symptoms before referral and a longer interval between presentation to the GP and receiving a diagnosis. Most people agreed a treat-to-target strategy but fewer DMARDs were commenced for patients with PsA than those for patients with RA and a lower improvement in disease activity was achieved at 3 months, suggesting undertreatment.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":"970-978"},"PeriodicalIF":20.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143750837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obesity substantially impacts rheumatic and musculoskeletal diseases: time to act.","authors":"Naveed Sattar, Lindsey J Sattar, Iain B McInnes, Stefan Siebert, Lyn D Ferguson","doi":"10.1016/j.ard.2025.02.013","DOIUrl":"10.1016/j.ard.2025.02.013","url":null,"abstract":"<p><p>Obesity is a major health problem and risk factor for many chronic health conditions, including rheumatic and musculoskeletal diseases (RMDs). Around 7 in 10 adults with RMD live overweight or with obesity. Obesity not only increases the risk of developing RMDs. It worsens disease activity, pain, and fatigue; impairs treatment responses; and thereby reduces quality of life and physical function. Further, obesity can amplify or drive several comorbidities that are more prevalent in RMDs including hypertension, cardiovascular disease, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease. Moreover, reciprocal risk arises since RMDs make it harder to be physically active and maintain a healthy weight, especially in the context of an obesogenic environment. In this viewpoint, we review relevant evidence to suggest obesity confers distinctive, important challenges in care and daily living for many patients with RMDs. With the advent of several highly effective drugs for obesity, we also highlight research needs including that for robust clinical trials to test the efficacy and effectiveness of these therapies as part of the management of inflammatory RMDs, as primary agent or adjuvant to immune targeted therapeutics. Implementing such weight management strategies should provide a much-needed holistic approach to the care of our patients.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":"894-898"},"PeriodicalIF":20.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143639374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Injury and obesity differentially and synergistically induce dysregulation of synovial immune cells in osteoarthritis.","authors":"Natalia S Harasymowicz, Zainab Harissa, Neda Rashidi, Kristin Lenz, Ruhang Tang, Farshid Guilak","doi":"10.1016/j.ard.2025.03.001","DOIUrl":"10.1016/j.ard.2025.03.001","url":null,"abstract":"<p><strong>Objectives: </strong>The heterogeneity and phenotype of immune cells orchestrate many physiologic and pathologic processes. Recent evidence suggests that immune cells play critical roles in the progression of osteoarthritis (OA). We hypothesised that injury and obesity, two major risk factors for OA, affect the immunophenotype of the synovium, the primary reservoir of immune cells in the joint.</p><p><strong>Methods: </strong>Using single-cell transcriptomics, immunoprofiling, transgenic mouse models, and genetic fate mapping methods, we characterised the presence and fate of multiple populations of immune cells found in the knee joint capsule.</p><p><strong>Results: </strong>We found that joint injury and obesity differentially and synergistically alter the architectural, cellular, and molecular profiles of the synovial capsule. We observed fewer patrolling monocytes in obese animals and found a significantly higher influx of proinflammatory monocyte-derived macrophages in the first 3 days after joint injury in obese compared with that in control animals. We also showed a significant loss of barrier-forming synovial lining macrophages 3 days after destabilisation of medial meniscus surgery, with a significant restoration of their numbers in normal weight but not in obese mice in advanced stages of OA. Finally, we characterised the presence and changes of other immune cell subtypes, including T, B, and mast cells and neutrophils, as well as local synovial fluid cytokines associated with injury and obesity.</p><p><strong>Conclusions: </strong>Our data revealed that injury and obesity independently and synergistically contribute to the dysregulation of the synovial immune landscape, providing new insight into their role in the pathogenesis of OA.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":"1033-1044"},"PeriodicalIF":20.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143787588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}